Abstract
The long-term safety and efficacy of synthetic 1,25-(OH)2D3 (calcitriol; Rocaltrol®) in the treatment of women with type 1 osteoporosis is being assessed in a randomized trial. Patients were allocated in double-blind fashion to 1,25-(OH)2D3 or matching placebo. Initially, the calcium intake was adjusted to 1,000 mg/d. The study protocol called for increasing the dose of 1,25-(OH)2D3 until patients developed either hypercalcemia or hypercalciuria. However, in order to maintain a higher dose of calcitriol on a long-term basis, the calcium intake had to be reduced to 600 mg/d in those receiving calcitriol; if that was not successful in eliminating hypercalcemia and hypercalciuria, then the dose of 1,25-(OH)2D3 was reduced as necessary. During the hypercalcemic phase, the indices of bone resorption decreased significantly, demonstrating that calcium absorption is solely responsible for hypercalcemia. The maintenance dose was established after 8 to 10 weeks, and the 24-hour urine calcium and creatinine clearance remained constant throughout the remainder of the study period. On a calcium intake of 600 mg/d, the long-term maintenance dose of 1,25-(OH)2D3 averaged 0.675 μg/d. Long-term therapy on an average dose of 0.675 μg/d was not associated with nephrotoxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 27-29 |
| Number of pages | 3 |
| Journal | Metabolism: Clinical and Experimental |
| Volume | 39 |
| Issue number | 4 SUPPL. 1 |
| DOIs | |
| State | Published - 1990 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Metabolic effects of synthetic calcitriol (Rocaltrol®) in the treatment of postmenopausal osteoporosis. / Gallagher, John Christopher G.
In: Metabolism: Clinical and Experimental, Vol. 39, No. 4 SUPPL. 1, 1990, p. 27-29.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metabolic effects of synthetic calcitriol (Rocaltrol®) in the treatment of postmenopausal osteoporosis
AU - Gallagher, John Christopher G.
PY - 1990
Y1 - 1990
N2 - The long-term safety and efficacy of synthetic 1,25-(OH)2D3 (calcitriol; Rocaltrol®) in the treatment of women with type 1 osteoporosis is being assessed in a randomized trial. Patients were allocated in double-blind fashion to 1,25-(OH)2D3 or matching placebo. Initially, the calcium intake was adjusted to 1,000 mg/d. The study protocol called for increasing the dose of 1,25-(OH)2D3 until patients developed either hypercalcemia or hypercalciuria. However, in order to maintain a higher dose of calcitriol on a long-term basis, the calcium intake had to be reduced to 600 mg/d in those receiving calcitriol; if that was not successful in eliminating hypercalcemia and hypercalciuria, then the dose of 1,25-(OH)2D3 was reduced as necessary. During the hypercalcemic phase, the indices of bone resorption decreased significantly, demonstrating that calcium absorption is solely responsible for hypercalcemia. The maintenance dose was established after 8 to 10 weeks, and the 24-hour urine calcium and creatinine clearance remained constant throughout the remainder of the study period. On a calcium intake of 600 mg/d, the long-term maintenance dose of 1,25-(OH)2D3 averaged 0.675 μg/d. Long-term therapy on an average dose of 0.675 μg/d was not associated with nephrotoxicity.
AB - The long-term safety and efficacy of synthetic 1,25-(OH)2D3 (calcitriol; Rocaltrol®) in the treatment of women with type 1 osteoporosis is being assessed in a randomized trial. Patients were allocated in double-blind fashion to 1,25-(OH)2D3 or matching placebo. Initially, the calcium intake was adjusted to 1,000 mg/d. The study protocol called for increasing the dose of 1,25-(OH)2D3 until patients developed either hypercalcemia or hypercalciuria. However, in order to maintain a higher dose of calcitriol on a long-term basis, the calcium intake had to be reduced to 600 mg/d in those receiving calcitriol; if that was not successful in eliminating hypercalcemia and hypercalciuria, then the dose of 1,25-(OH)2D3 was reduced as necessary. During the hypercalcemic phase, the indices of bone resorption decreased significantly, demonstrating that calcium absorption is solely responsible for hypercalcemia. The maintenance dose was established after 8 to 10 weeks, and the 24-hour urine calcium and creatinine clearance remained constant throughout the remainder of the study period. On a calcium intake of 600 mg/d, the long-term maintenance dose of 1,25-(OH)2D3 averaged 0.675 μg/d. Long-term therapy on an average dose of 0.675 μg/d was not associated with nephrotoxicity.
UR - http://www.scopus.com/inward/record.url?scp=0025317106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025317106&partnerID=8YFLogxK
U2 - 10.1016/0026-0495(90)90268-H
DO - 10.1016/0026-0495(90)90268-H
M3 - Article
C2 - 2325568
AN - SCOPUS:0025317106
VL - 39
SP - 27
EP - 29
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 4 SUPPL. 1
ER -